KRAS-G12C in the crosshairs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.Clinical lung cancer · 2020
   Trial
2. Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?Journal of medicinal chemistry · 2025
   Review
3. The value of protein allostery in rational anticancer drug design: an update.Expert opinion on drug discovery · 2024
   Review
4. Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways.World journal of gastrointestinal oncology · 2023
   Review
5. Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.Targeted oncology · 2023
   Review
6. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.Molecular imaging and biology · 2022
   Article
7. Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.The Journal of experimental medicine · 2022
   Article
8. Inhibition of colon cancer K-RasFrontiers in pharmacology · 2022
   Article
9. Discovery of novel KRAS‒PDEActa pharmaceutica Sinica. B · 2022
   Article
10. Anticancer drug resistance: An update and perspective.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2021
    Review
11. Virtual clinical trial simulations for a novel KRASCPT: pharmacometrics & systems pharmacology · 2021
    Article
12. Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation.Cancers · 2021
    Article
13. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.BMC cancer · 2021
    Article
14. Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS.MedComm · 2020
    Article
15. Targeted Degradation of Oncogenic KRASACS central science · 2020
    Article
16. Role of imaging biomarkers in mutation-driven non-small cell lung cancer.World journal of clinical oncology · 2020
    Review
17. TargetingInternational journal of molecular sciences · 2020
    Review
18. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.Metabolomics : Official journal of the Metabolomic Society · 2020
    Article

Corrections and comments

• Comment on
  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.2019
• Comment on
  The KRAS2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as